Researchers hope to decrease chemo in breast cancer patients
Apr 27, 2011
Scientists at Genomic Health, Inc., as well as the University of Michigan will begin a large clinical trial called RxPONDER in order to determine which women with hormone receptor-positive breast cancer require chemotherapy treatment.
RxPONDER stands for Rx for Positive Node, Endocrine Responsive Breast Cancer.
The Oncotype DX test will be used to see if a patient is likely to have a recurrence of cancer.
"Based on results from the previous ...studies, which support the use of Oncotype DX in patients with node-positive breast cancer, as well as positive results from a decision impact study recently published in the Journal of Oncology Practice, many physicians have used the Oncotype DX test in their patients with node-positive breast cancer and certain payors have started covering the test's use in these patients," said the chief medical officer of Genomic Health, Steven Shak.
About 60,000 women are diagnosed each year with hormone receptor-positive breast cancer, according to Ana Gonzalez-Angulo of the MD Anderson Cancer Center.
This is compared to more than 200,000 women who are diagnosed with any type of breast cancer yearly.